{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:28:54Z","timestamp":1792700934241,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Glucocorticoid (GC) therapies treat many chronic conditions such as congenital adrenal hyperplasia (CAH), but long-term use carries risks of side effects (e.g., skeletal, cardiometabolic, mental health issues) that can negatively impact clinical and economic outcomes. Consequently, patients and providers seek to balance the lowest efficacious dose and side effect risk. To our knowledge, no research has analyzed US payer coverage decisions on medications that reduce GC reliance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To understand the significance and implications of US payer perceptions and coverage\/access decisions for therapies reducing GC doses, which may be of relevance to new therapies for CAH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A literature review was paired with primary market research to identify and characterize 5 GC-reducing therapies to evaluate payer coverage policies. No identified therapies were currently approved or studied in CAH. Qualitative interviews (n=13) were also conducted across managed care organizations, pharmacy benefit managers, and managed Medicaid payers to supplement publicly available information.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>GC-reducing therapies were desirable and therapeutically beneficial from payer perspectives based on market research of payer coverage policies; all therapies were covered in place of or in addition to GCs. Despite premium pricing vs. low-cost alternatives, all therapies evaluated were covered by some or all payers with prior authorization to label indication or trial criteria. Qualitative interviews revealed that payers clearly understood the clinical burden of long-term GC use; however, the economic burden was less understood. Payers stated that GC reduction is a secondary decision-making driver due to the focus on trial primary endpoints, contracting dynamics, lack of competitors, and small trial sample sizes. A subset of payers was interested in GC reduction data as a primary endpoint for rare diseases without treatment alternatives and in pediatric populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite the premium price over GCs, GC-reducing therapies were covered in place of or in addition to GCs. Payers acknowledged the clinical value of reducing long-term GC use. Understanding what payers perceive as important criteria for coverage of GC-reducing medication may aid clinicians in evaluating utilization management criteria, such as step therapy, and increase access to medications aiming to reduce the patient burden associated with long-term GC use. This is particularly important in CAH where there is a high unmet need due to lifelong exposure to supraphysiologic doses of GCs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1603701","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:18:32Z","timestamp":1757391512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing glucocorticoid therapy in congenital adrenal hyperplasia and analog conditions: the intersection of dose reduction, patient care, and coverage in the US"],"prefix":"10.3389","volume":"16","author":[{"given":"Ahmed","family":"Khattab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mulrooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leinwand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Hadker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13091264","article-title":"Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects","volume":"171","author":"Judd","year":"2014","journal-title":"Am J Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22574","article-title":"Glucocorticoid use in patients with systemic Lupus erythematosus: association between dose and health care utilization and costs","volume":"67","author":"Chen","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: A systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-016-1435-y","article-title":"Health-related quality of life associated with systemic corticosteroids","volume":"26","author":"Sullivan","year":"2017","journal-title":"Qual Life Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"383","author":"Merke","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2015.02.002","article-title":"Adrenal steroidogenesis and congenital adrenal hyperplasia","volume":"44","author":"Turcu","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/EJE-12-0161","article-title":"Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency","volume":"167","author":"Reisch","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1440","article-title":"Approach to the patient: the adult with congenital adrenal hyperplasia","volume":"98","author":"Auchus","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.119491","article-title":"Congenital adrenal hyperplasia: Treatment and outcomes","volume":"17","author":"Kamoun","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B14","volume-title":"BENLYSTA (belimumab)","year":"2011"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000118","article-title":"Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA","volume":"3","author":"Collins","year":"2016","journal-title":"Lupus Sci Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic Lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B19","volume-title":"KEVZARA (sarilumab)","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.3.237","article-title":"Methodology for conducting a comprehensive product review in managed care","volume":"29","author":"Linnerooth","year":"2023","journal-title":"J Managed Care Specialty Pharm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00184-5","article-title":"Retrospective analysis of the impact of adalimumab initiation on corticosteroid utilization and medical costs among biologic-naive patients with rheumatoid arthritis","volume":"7","author":"Spivey","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B23","volume-title":"HUMIRA (adalimumab)","year":"2002"},{"key":"B24","volume-title":"EXONDYS 51 (eteplirsen)","year":"2016"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180351","article-title":"Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with duchenne muscular dystrophy","volume":"6","author":"Khan","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"B26","volume-title":"ARCALYST (rilonacept)","year":"2008"},{"key":"B27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302013000200005","article-title":"Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism","volume":"57","author":"Cordeiro","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jpeds.2014.01.011","article-title":"Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort","volume":"164","author":"Sarafoglou","year":"2014","journal-title":"J Pediatr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2016.06.015","article-title":"Quality of life in patients with adrenal insufficiency correlates stronger with hydrocortisone dosage, than with long-term systemic cortisol levels","volume":"72","author":"Andela","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1096","article-title":"Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency","volume":"174","author":"Schulz","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0397","article-title":"The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients","volume":"171","author":"Ragnarsson","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1530\/EJE-08-0880","article-title":"Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone","volume":"160","author":"Lovas","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.126601","article-title":"Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"141","author":"Muirhead","year":"2002","journal-title":"J Pediatr"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2019-0006","article-title":"Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty","volume":"32","author":"Pijnenburg-Kleizen","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199701000-00005","article-title":"Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height","volume":"41","author":"Jaaskelainen","year":"1997","journal-title":"Pediatr Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000515833","article-title":"Bone mass in young patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"94","author":"Espinosa Reyes","year":"2021","journal-title":"Horm Res Paediatr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13060","article-title":"A model for measuring the health burden of classic congenital adrenal hyperplasia in adults","volume":"85","author":"Hummel","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2015-2093","article-title":"Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: A Swedish population-based national cohort study","volume":"100","author":"Falhammar","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0917","article-title":"Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients","volume":"95","author":"Arlt","year":"2010","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1603701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:18:34Z","timestamp":1757391514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1603701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":40,"alternative-id":["10.3389\/fendo.2025.1603701"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1603701","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"1603701"}}